Results 21 to 30 of about 462,488 (300)

Diabetes: how to manage cardiovascular risk in secondary prevention patients

Drugs in Context, 2022
Atherosclerotic cardiovascular disease (ASCVD) commonly affects people with type 2 diabetes (T2D). Historically, traditional cardiovascular (CV) risk-lowering therapies in patients with T2D and ASCVD have included antiplatelet agents, blood pressure ...
Sarah L Anderson, Joel C Marrs
doaj   +1 more source

Comparative cost-effectiveness analyses of cardiovascular magnetic resonance and coronary angiography combined with fractional flow reserve for the diagnosis of coronary artery disease. [PDF]

, 2014
According to recent guidelines, patients with coronary artery disease (CAD) should undergo revascularization if significant myocardial ischemia is present.
Pilz, G., Steffen E Petersen, Pilz, G, Petersen, SE, Wasserfallen, J-B, Guenter Pilz, Petersen, S.E., Favre, David, Petersen, Steffen E., Anja Wagner, Schwitter, J.J., Pinget, C, Favre, D., Wagner, A, Wagner, A., Jean-Blaise Wasserfallen, Karine Moschetti, Moschetti, K., Moschetti, Karine, Wasserfallen, JB, Schwitter, J, Schwitter, Juerg, Wasserfallen, Jean-Blaise, David Favre, Schwitter, JJ, Christophe Pinget, Pinget, Christophe, Wasserfallen, J.B., Pilz, Guenter, Pinget, C., Wagner, Anja, Juerg J Schwitter, Moschetti, K, Favre, D   +33 more
core   +1 more source

Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists

American Journal of Preventive Cardiology, 2023
Cardiovascular disease remains one of the most prominent global health problems and has been demonstrated to disproportionally affect certain communities.
Apurva Khedagi, Cara Hoke, Michelle Kelsey, Andrea Coviello, W. Schuyler Jones, Larry R. Jackson, II, Manesh R Patel, Rob W. McGarrah, Neha J Pagidipati, Nishant P. Shah   +9 more
doaj   +1 more source

Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management [PDF]

, 2022
Cardiovascular diseases (CVDs) are the main cause of death among patients with type 2 diabetes mellitus (T2DM), particularly in low- and middle-income countries. To effectively prevent the development of CVDs in T2DM, considerable effort has been made to
Ma, Xiao-Ni, Mauricio Puente, Dídac, Li, Ying-Dong, Ma, Cheng-Xu, Universitat Autònoma de Barcelona, Guan, Cong-Hui, Fu, Song-Bo, Mauricio, Dídac   +7 more
core   +1 more source

The impact of cardiovascular drugs on the efficacy of local anesthesia in dentistry

Biomedical Papers, 2016
Background and Aim. Drugs used chronically by patients with diseases of the cardiovascular system (group C of the ATC classification) may act on adrenergic receptors and/or certain ion channels, which gives them the potential to interact with the action
Мarko J. Milosavljevic, Slobodan M. Jankovic   +1 more
doaj   +1 more source

Production and market comparison of urokinase and streptokinase as effective and cheap fibrinolytic agents for treatment of cardiovascular diseases

Acta Scientiarum: Technology, 2022
 Failure of hemostasis and the formation of blood clots in the arteries are the main reasons that provoke the onset of cardiovascular diseases (CVDs) such as myocardial infarction and ischemic stroke.
Ali Nawaz, Ikram ul Haq, Haseeb Amin, Zinnia Shah, Ammar Javed, Hamid Mukhtar, Fatima Akram   +6 more
doaj   +1 more source

Ranolazine: A true pluripotent cardiovascular drug or jack of all trades, master of none?

Sultan Qaboos University Medical Journal, 2018
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide. Although the majority of patients with CVD are treated with interventional procedures, a substantial number require medical therapy in terms of both prognosis and ...
Alice Mezincescu, V. J. Karthikeyan, Sunil K. Nadar   +2 more
doaj   +1 more source

Does sticky blood predict a sticky end? Associations of blood viscosity, haematocrit and fibrinogen with mortality in the West of Scotland [PDF]

, 2003
There is increasing evidence that blood viscosity and its major determinants (haematocrit, plasma viscosity and fibrinogen) are associated with an increased risk of incident cardiovascular events; however, their associations with mortality are not ...
Lowe, G.D.O., Rumley, A., Tunstall-Pedoe, H., Woodward, M.   +3 more
core   +1 more source

More hemodynamic changes in hypertensive versus non-hypertensive patients undergoing breast cancer surgery in general anesthesia - a prospective clinical study [PDF]

Medicinski Glasnik, 2009
Aim Preoperative comorbidity may significantly influence theconduction of anesthesia and patients’ outcome. The aim of thisstudy was to compare a number of anesthetic interventions and theuse of non-anesthetic drugs in hypertensive and non ...
Darija Azenić-Venžera, Kata Šakić, Jozo Kristek, Ivana Drenjančević-Haršanji, Andreja Rakipović-Stojanović, Gordana Brozovic, Slavica Kvolik, Dražen Vidović, Borna Kovačić, Gordana Kristek   +9 more
doaj  

Pharmacology of cardiovascular chronotherapeutic agents [PDF]

American Journal of Hypertension, 2001
Although sudden cardiac death, myocardial infarction, or stroke can occur at any time of day, event rates increase during the waking hours, particularly in the morning. In most people-both normotensive and hypertensive-blood pressure (BP) rises rapidly in the early morning hours, the time when most individuals wake and begin their day.
openaire   +2 more sources